Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Active not recruiting × Solid Tumors × pralsetinib × Clear all

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Interventions

pembrolizumab 3 olaparib 2 atezolizumab 2 Trastuzumab 2 zimberelimab 1 tocilizumab 1 spartalizumab 1 pralsetinib 1 pertuzumab 1 ipatasertib 1 inavolisib 1 fludarabine 1 entrectinib 1 alectinib 1 Radiotherapy 1 Methotrexate 1 Immune Checkpoint Inhibitors 1 Docetaxel 1 Cyclophosphamide 1 Ado-Trastuzumab Emtansine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04589845 2026-04-02

Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study

Hoffmann-La Roche

Phase 2 Active not recruiting

920 enrolled 2 FDA

Other solid neoplasm

Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon ⚡